NovoCure Ltd (NASDAQ: NVCR) is -19.29% lower on its value in year-to-date trading and has touched a low of $10.87 and a high of $83.60 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NVCR stock was last observed hovering at around $12.05 in the last trading session, with the day’s loss setting it 0.0%.
Currently trading at $12.05, the stock is -13.39% and -18.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.39 million and changing 0.00% at the moment leaves the stock -35.52% off its SMA200. NVCR registered -81.07% loss for a year compared to 6-month loss of -22.90%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -11.00% gain in the last 1 month and extending the period to 3 months gives it a -16.90%, and is -14.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.25% over the week and 6.36% over the month.
NovoCure Ltd (NVCR) has around 1453 employees, a market worth around $1.29B and $509.34M in sales. Profit margin for the company is -40.65%. Distance from 52-week low is 10.86% and -85.59% from its 52-week high. The company has generated returns on investments over the last 12 months (-21.60%).
The EPS is expected to grow by 9.89% this year
The shares outstanding are 107.08M, and float is at 96.28M with Short Float at 5.20%.
NovoCure Ltd (NVCR) Insider Activity
The most recent transaction is an insider sale by GROENHUYSEN WILHELMUS CM, the company’s Chief Operating Officer. SEC filings show that GROENHUYSEN WILHELMUS CM sold 1,217 shares of the company’s common stock on Mar 04 ’24 at a price of $16.01 per share for a total of $19484.0. Following the sale, the insider now owns 0.25 million shares.
NovoCure Ltd disclosed in a document filed with the SEC on Mar 04 ’24 that Leonard Frank X (EVP, Pres., Novocure Oncology) sold a total of 840 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $16.01 per share for $13448.0. Following the transaction, the insider now directly holds 0.16 million shares of the NVCR stock.
Still, SEC filings show that on Mar 01 ’24, GROENHUYSEN WILHELMUS CM (Chief Operating Officer) disposed off 2,107 shares at an average price of $16.03 for $33769.0. The insider now directly holds 252,452 shares of NovoCure Ltd (NVCR).
